Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 38Lymphoma, Follicular 14Lymphoma, Non-Hodgkin 9Waldenstrom Macroglobulinemia 8Lymphoma, B-Cell, Marginal Zone 7Lymphoma, Mantle-Cell 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, B-Cell 4Lymphoma 4Leukemia, Myeloid, Acute 4Leukemia 4Lymphoma, Large B-Cell, Diffuse 3Neoplasm Metastasis 2Multiple Myeloma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, B-Cell 2Hodgkin Disease 2Thrombocytosis 1Signs and Symptoms, Digestive 1Recurrence 1Prostatic Neoplasms 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoid Malignancies 1Leukemia, Prolymphocytic 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 98Fluorouracil 90Capecitabine 86Dexamethasone 81Radiotherapy 80Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Leucovorin 64Drug Therapy 64Cetuximab 60Erlotinib Hydrochloride 56Sorafenib 53atezolizumab 52Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × idelalisib × Clear all
NCT02258529 2019-05-14

Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma

Gilead Sciences

Phase 2 Terminated
10 enrolled 10 charts
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡